Antitumor Activity of Sorafenib Plus CDK4/6 Inhibitor in Pancreatic Patient Derived Cell With KRAS Mutation

Journal of Cancer - Australia
doi 10.7150/jca.26068
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Ivyspring International Publisher

Related search

The Impact of Cetuximab Plus AKT- Or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model With Wild-Type RAS and PIK3CA Mutation

Journal of Cancer
Oncology
2017English

The Novel ATM Inhibitor (AZ31) Enhances Antitumor Activity in Patient Derived Xenografts That Are Resistant to Irinotecan Monotherapy

Oncotarget
Oncology
2017English

GC1118, a Novel Anti-Egfr Antibody, Has Potent KRAS Mutation-Independent Antitumor Activity Compared With Cetuximab in Gastric Cancer

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2019English

Antitumor Effect of Sorafenib and mTOR Inhibitor in Liver Transplantation Recipients With Hepatocellular Carcinoma Recurrence

Liver Transplantation
HepatologyTransplantationSurgery
2018English

Interferon-Alpha Plus Sorafenib Combination Shows Efficacy and Improved Patient Outcome in Renal Cell Cancer

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2007English

KRAS Mutation, KRAS–LCS6 Polymorphism, and Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2010English

Targeting CDK4/6 in Patients With Cancer

Cancer Treatment Reviews
MedicineOncologyRadiologyNuclear MedicineImaging
2016English

A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma

Clinical Cancer Research
Cancer ResearchOncology
2018English

Preclinical Evaluation of Biomarkers Associated With Antitumor Activity of MELK Inhibitor

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy